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Abstract
Objective: To evaluate if subclinical thyroid dysfunction is associated with cardiovascular 
(CV) risk in patients with atrial fibrillation (AF).
Methods: Swiss-AF is a prospective cohort of community-dwelling participants aged ≥ 65 
years with AF. Primary outcome was a composite endpoint of CV events (myocardial 
infarctions, stroke/transitory ischemic events, systemic embolism, heart failure (HF) 
hospitalizations, CV deaths). Secondary outcomes were component endpoints, total mortality 
and AF-progression. Exposures were thyroid dysfunction categories, TSH and fT4. Sensitivity 
analyses were performed for amiodarone use, thyroid hormones use and competing events.
Results: 2415 patients were included (mean age 73.2 years; 27% women). 196 (8.4%) had 
subclinical hypothyroidism and 53 (2.3%) subclinical hyperthyroidism. Subclinical thyroid 
dysfunction was not associated with CV events, during a median follow-up of 2.1 years (max 
5 years): age- and sex- adjusted hazard ratio (adjHR) of 0.99 (95% confidence interval (CI) 
0.69-1.41) for subclinical hypothyroidism; and 0.55 (95%CI 0.23-1.32) for subclinical 
hyperthyroidism. Results remained robust following multivariable adjustment and sensitivity 
analyses. In euthyroid patients, fT4 levels were associated with an increased risk for the 
composite endpoint and HF (adjHR 1.46 95%CI 1.04- 2.05; adjHR 1.70 95%CI 1.08-2.66, 
respectively, for the highest quintile versus the middle quintile). Results remained similar 
following multivariable adjustment. Results remained significant for HF in sensitivity 
analyses. No association between subclinical thyroid dysfunction and total mortality or AF-
progression was found. 
Conclusions: Subclinical hypothyroidism was not associated with increased CV risk in AF 
patients. Higher levels of fT4 with normal TSH were associated with higher risk for HF. 
Key words: Thyroid; atrial fibrillation; cardiovascular outcomes, heart failure
Word count: 248 words
Page 3 of 42 Accepted Manuscript published as EJE-20-1442.R4. Accepted for publication: 02-Jul-2021
Copyright © 2019 European Society of EndocrinologyDownloaded from Bioscientifica.com at 07/13/2021 08:07:06AM
via Universitatsbibliothek Bern and Universitat Bern
4
Introduction
Subclinical thyroid dysfunction, which includes subclinical hypothyroidism and subclinical 
hyperthyroidism (defined as elevated or decreased TSH, respectively, with fT3 and fT4 in the 
normal range) is frequent with subclinical hypothyroidism occurring in up to 12% among 
elderly and subclinical hyperthyroidism in up to 6% of the general population (1). Subclinical 
thyroid disease has been associated with an increased risk of coronary heart disease (CHD) 
events and cardiovascular (CV) mortality (2, 3) as well as with an increased risk of heart 
failure (HF) events, particularly for TSH levels < 0.1 mIU/L and >10 mIU/L(4, 5). The risk of 
stroke may also be increased in younger patients with subclinical hypothyroidism (6). Thyroid 
dysfunction is also associated with atrial fibrillation (AF) (3, 7-11), with a prevalence of up to 
22% in hyperthyroid subjects (12) compared to 3% in the general population (13). Subclinical 
hyperthyroidism has been associated with a >5-fold increased AF risk (14). Furthermore, 
development of AF is an adverse effect of overtreatment of hypothyroidism (15) and higher 
circulating fT4 levels even in persons with normal TSH levels have been associated with 
increased AF risk and HF events (8, 16). 
AF may be progressive and 3 types of AF are recognized in clinical practice: paroxysmal (AF 
that terminates spontaneously within 7 days), persistent (AF that does not terminate 
spontaneously within 7 days) or permanent AF (no rhythm control can be achieved) (17). 
Progression of paroxysmal or persistent to permanent AF has been associated with an 
increased risk of ischemic stroke, cardiac dysfunction and mortality (18-21). Previous data 
has found that history of hyperthyroidism may be a risk factor for AF-progression (Hazard 
Ratio (HR) 1.71; 95% CI, 1.16-2.52) (18). 
The association between thyroid dysfunction and adverse CV events in participants with 
established AF remains unclear (22-24). Previous studies have suggested that a history of 
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hyperthyroidism in participants with AF represents an independent risk factor for stroke (22, 
24), with conflicting results in other studies (23, 25). Subclinical thyroid dysfunction is a 
common diagnosis in patients with AF (26), and its association with stroke in the AF 
population has not been previously examined. In addition, AF population may differ 
substantially in comparison to the general population in terms of treatments as well as 
comorbidities and outcomes (27), making the investigation of the association between 
subclinical thyroid dysfunction and CV events and thus identification of modifiable risk 
factors particularly relevant. Furthermore, taking into account the direct cardio metabolic 
effects of thyroid hormones, it is not known whether thyroid dysfunction induces an AF-
progression.
This study’s primary aim was to examine if subclinical thyroid dysfunction was associated 
with higher CV risk and secondary if subclinical thyroid dysfunction is associated with total 
mortality or AF-progression in AF patients.
Methods
The Swiss-AF 
The study protocol has been previously described (28). Swiss-AF is a prospective multicenter 
observational cohort study conducted in 14 centers in Switzerland (4 university hospitals and 
10 cantonal hospitals). Main inclusion criteria were age ≥ 65 years and AF. In addition, we 
aimed to enroll 10% to 15% of patients between 45 and 65 years of age to assess the effects of 
AF on individuals in the active workforce (29). Main exclusion criteria were inability to 
provide informed consent, the presence of exclusively non-sustained episodes of secondary 
AF or any acute illness in the last 4 weeks. Eligible candidates for enrolment in Swiss-AF 
were obtained by comprehensive screening of in- and outpatients in participating hospitals 
and by contacting general practitioners. The study complies with the Declaration of Helsinki. 
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The local ethics committees approved the study protocol and written informed consent was 
obtained from all participants. All study sites received the approval of their cantonal ethical 
committee. The ethical committees involved were the following: Northwest and central 
Switzerland, Bern, Geneva, Vaud, Saint Gall, Ticino and Zurich.
Non-fasting venous blood samples were collected from each patient at baseline and stored at 
−80°C. Participants gave their consent for the storage of their blood samples in the biobank as 
well as the use for further projects. For the current project, thyroid function measurement was 
performed in all participants with available blood samples (97%). Electrochemiluminescence 
immunoassays for TSH and fT4 were performed using the Elecsys detection method (cobas 
Elecsys, Roche Diagnostics GmbH, Mannheim, Germany). Thyroid function was defined as 
follows: overt hyperthyroidism (TSH<0.45 mIU/L with elevated fT4), subclinical 
hyperthyroidism (TSH<0.45 mIU/L with fT4 within the reference range), subclinical 
hypothyroidism (TSH 4.51-19.99 mIU/L with fT4 level within the reference range), overt 
hypothyroidism (TSH≥20.00 mIU/L or TSH>4.50 mIU/L with fT4 level below the reference 
range) and euthyroidism (TSH 0.45-4.50 mIU/L with fT4 within the reference range) (30).
Patient and Public Involvement statement
Patients and/or the public were not involved in the design, conduct, reporting or dissemination 
plans of this research.
Outcomes and Covariates
The primary outcome was a composite endpoint of CV events (myocardial infarctions (MIs), 
stroke/transitory ischemic events (TIAs), systemic embolism, hospitalizations for or HF and 
CV deaths). If a clinical outcome measure is reported by the patient or detected in the medical 
records, detailed information is collected from the corresponding hospitals and/or treating 
physicians about this event. The clinical events were adjudicated by a blinded event 
committee, which was not aware of thyroid function (28). Secondary outcomes were the 
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components of the composite endpoint, total mortality and AF-progression. AF-progression 
was defined as 1) AF-progression from paroxysmal AF at baseline to non-paroxysmal AF 
(persistent or permanent AF) at the latest follow-up or as AF-progression from persistent AF 
at baseline to permanent AF at the latest follow-up (persistent if ECG during follow-up 
showed AF and did not show AF in previous study visits, permanent AF if a decision by the 
patient and physician not to pursue a rhythm control strategy was made) (clinical AF-
progression) or 2) the need for rhythm control intervention (RCI) [antiarrhythmic intervention 
(either electro conversion (ECV) and/or pulmonary vein isolation (PVI) and/or start with 
amiodarone)] (18). 
Statistical Analysis
Baseline characteristics were described separately for euthyroid participants, subclinical 
hypothyroid and subclinical hyperthyroid participants and also according to fT4 quintiles.
For the primary outcome we described the rates of CV outcomes in the above mentioned 
patient groups and examined the overall association of subclinical thyroid dysfunction and 
CV outcomes using Cox proportional-hazards models. We analyzed the associations 
separately for the following subgroups: euthyroid participants, subclinical hypothyroid and 
subclinical hyperthyroid participants and then with TSH as a continuous variable (within 
normal fT4) and as TSH quintiles. Secondary outcomes of the association of thyroid 
dysfunction with AF-progression were also analyzed using Cox proportional-hazards models. 
The same analyses were used for fT4 as continuous and fT4 quintiles as an exposure in the 
euthyroid individuals (each quintile represents 20% of the population with the middle quintile 
representing most of the population). We have checked the proportionality of the hazards 
function and it was fulfilled (8). There was no evidence against linearity using cubic splines 
regression (31).
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All the analyses were first adjusted for age and sex and in a following step, additional 
adjustment were done for smoking and body mass index (BMI), as these potential 
confounders may have an influence on thyroid function and the outcomes. Further, we 
performed post-hoc covariate adjustment for baseline imbalances: diabetes, previous CV 
disease, previous HF, previous ECV, use of amiodarone, use of thyroid hormones, and 
hypothyroidism (32). We conducted subgroup analyses excluding patients taking thyroid 
hormone replacement and/or antithyroid medications at baseline. We also performed 
sensitivity analyses excluding patients who started “new” thyroid hormone replacement 
and/or antithyroid medications during follow-up. Since amiodarone could lead to changes in 
thyroid function, we performed sensitivity analyses excluding patients taking amiodarone at 
baseline. Most of the covariates -apart from age and BMI- were self-reported and there were 
very few values missing (See Table 1 footnotes). We also performed stratified analyses in 
subclinical hypothyroidism categories based on TSH: TSH 4.51-6.99 mIU/L and TSH 7.00-
19.99 mIU/L (2). 
Even though also adjudicated, since TIAs constitute a clinical diagnosis, we performed 
sensitivity analyses excluding TIAs from the composite outcome.  Further, we performed 
sensitivity analyses taking center into account by using mixed-effects Cox regression models. 
For the primary endpoint we performed sensitivity analyses using competing risk regression 
for mortality, using Fine-Gray subdistribution hazard models (33). The method yields sub 
hazard ratios (SHR) with corresponding 95% CI.
Our study had >80% power to detect HR of 1.25 for the composite endpoint for subclinical 
hypothyroidism versus euthyroid persons.  Regarding subclinical hyperthyroidism, our study 
had less power, specifically our study had > 80% power to detect a HR of 1.65 for subclinical 
hyperthyroidism for the composite endpoint.
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Statistical analyses were performed with STATA version 16.0 (StataCorp, College 




Of 2415 patients included in Swiss-AF cohort (mean age 73.2 years; 27% women; 315 
patients (13%) of the total population under 65 years), TSH and fT4 measurement was 
complete in 2332 (97%) patients, which were included in the present analyses. Baseline 
characteristics of patients with (97%) and without blood samples (3%) did not show any 
meaningful differences (Table 1). Data on potentially eligible patients denying participation 
have not been systematically collected in all study centers. In the study centre of Bern (2nd 
largest study site), data on adults declining participation were collected over the full 
recruitment period of 39 months, and around 64% of possible eligible participants denied 
participation due to “study design related issues (“too complicated”)”, “lack of interest for 
participation in studies” or “age or health related issues”.
26 (1.1%) participants were lost to follow up (n=20 euthyroid participants, n=4 with 
subclinical hypothyroidism, n=1 with clinical hyperthyroidism, n=1 with clinical 
hypothyroidism). On baseline, 608 (26.1%) had a history of HF and 789 (33.6%) had a history 
of CV disease (Table 1). Comorbid conditions included hypertension (69.9%) and diabetes 
mellitus (17.4%). 1144 (49.1%) were taking statins at baseline, 407 (17.5%) were taking 
amiodarone and 229 (9.8%) were taking thyroid hormones. Median TSH level was 2.0 
mIU/L, median fT4 level was 16.0 pmol/L. Overall, 86.3% were euthyroid, 8.4% had 
subclinical hypothyroidism, 2.3% had subclinical hyperthyroidism, 1.5% had overt 
hyperthyroidism and 1.4% had overt hypothyroidism. 11 patients could not be classified on a 
thyroid function category because of incompatible TSH and fT4 values.
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Subclinical thyroid function and CV events
Over a median 2.1 years of follow-up (maximal 5 years), 394 composite endpoint events 
occurred. There were 65 Strokes and 23 TIAs, 6 systemic embolism events, 49 MIs, 129 
cardiac deaths and 227 HF events. After adjusting for age and sex, neither subclinical 
hypothyroidism (HR 0.99 95%CI 0.69-1.41) nor subclinical hyperthyroidism (HR 0.55 
95%CI 0.23-1.32) were associated with increased risk of the composite endpoint or the 
individual outcomes compared with euthyroidism (Table 2). For subclinical hypothyroidism 
with a TSH level of 7.00 to 19.99 mIU/L, there was a  no statistically significant association 
with the composite endpoint (HR 1.27 95%CI 0.76-2.13) (Table 2). Similar results were 
obtained in all models after adjusting for smoking and BMI as well as after adjusting for 
baseline imbalances: previous diabetes, previous CV disease, previous HF, previous ECV, 
baseline use of amiodarone, baseline use of thyroid hormones, and previous hypothyroidism 
(Appendix Table 1a). Results remained the same in stratified analyses according to baseline 
CV disease (p for interaction >0.05) (Appendix Table 1b).
TSH as a continuous variable (within normal fT4 levels) was not associated with CV events 
and the composite endpoint (Appendix Table 2). Sensitivity analyses with log transformation 
of TSH, to account for a not normal distribution, did not materially changed our results. 
Results remained similar in sensitivity analyses excluding patients with baseline thyroid 
altering medications (n=247) (Appendix Table 3), as well as excluding patients who initiated 
thyroid hormones during follow-up (n=56) (currently not shown) and after taking TSH-
quintiles as an exposure (currently not shown). Similar results were obtained using competing 
risk models accounting for all-cause death as a competing event (Appendix Table 4) and after 
excluding TIAs from the composite endpoint (currently not shown). 
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FT4 in euthyroid participants 
FT4 as a continuous variable among euthyroid participants was associated with the composite 
endpoint, HF events and CV death as well as overall mortality (Figure 1a, Appendix Table 5). 
Results remained significant for the composite endpoint and HF events after adjusting for age, 
sex, BMI and smoking as well as after excluding participants with baseline amiodarone or 
thyroid altering medications (Figure 1b, 1c, Appendix Table 5). Our results remained robust 
following sensitivity analyses after log transformation of fT4 levels.
Appendix Table 6 describes baseline characteristics according to fT4 quintiles. Euthyroid 
participants in the highest fT4 quintile compared with the middle quintile of fT4 levels 
showed a higher risk of the composite outcome (age- and sex-adjusted HR 1.46 95%CI 1.04- 
2.05) and HF events (age- and sex-adjusted HR 1.70 95%CI 1.08-2.66) (Table 3). Since 
participants in the highest quintile were considerably more often taking amiodarone at 
baseline (Appendix Table 6) we performed sensitivity analyses excluding patients under 
amiodarone and the results remained similar (Appendix Table 7). Participants in the highest 
quintile had more commonly history of HF at baseline, previous CV disease as well previous 
ECV (Appendix Table 6). Results did not change after taking these factors in the 
multivariable model (Appendix Table 8). A quarter of patients within the highest quintile of 
fT4 levels were on thyroid hormone supplementation (Appendix Table 6). After excluding 
patients with thyroid altering medications at baseline (n=157) as well as patients starting 
thyroid hormones during follow-up (n=18), results remained significant only for HF events 
(age- and sex-adjusted HR 1.83 95% CI 1.12-2.98). After excluding patients on thyroid 
altering medications, a significant association for the composite endpoint remained when fT4 
was analysed as a continuous outcome (HR 1.16 95% CI 1.10-1.28) per 5 Units increase in 
fT4), the same association was not significant when fT4 was analysed in quintiles (HR 1.36 
95% CI 0.94-1.97) for the highest quintile vs middle quantile) (Appendix Table 9). Results 
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remained significant for the composite endpoint and HF events after performing competing 
risks models accounting for all-cause death as a competing event (Appendix Table 10) and 
after excluding TIAs from the composite endpoint (currently not shown). Sensitivity analyses 
taking study center into account using mixed-effects Cox regression models did not materially 
change our results.
AF-progression
Clinical AF-progression occurred in 290 patients, while 234 patients had a rhythm control 
intervention. Neither subclinical hypothyroidism (age and sex-adjusted HR 1.05 95%CI 0.69-
1.60) nor subclinical hyperthyroidism (age and sex-adjusted HR 1.08 95%CI 0.53-2.18) were 
associated with increased risk of clinical AF-progression (Appendix Table 11). Similar results 
were obtained for pharmacological progression (Table 3). Results remained similar after 
additional adjustment for smoking and BMI (currently not shown). We also performed 
analyses using fT4 quintiles as an exposure with AF-progression as an outcome, and we found 
no association (currently not shown). 
Discussion
In this large prospective cohort, we investigated the association of subclinical thyroid 
dysfunction with CV events in patients with established AF. Subclinical thyroid dysfunction 
was not associated with CV events, mortality or AF-progression. However, higher levels of 
fT4 alone at baseline were associated with higher risk for HF hospitalizations.
The association between thyroid dysfunction- both overt and subclinical- with new onset AF 
is well established and thyroid function tests are recommended in all patients with new onset 
of AF (7, 9, 11, 34, 35).  However, the clinical and predictive significance of subclinical 
thyroid dysfunction in patients with established AF has not been previously investigated. A 
number of prospective cohort studies and individual participant meta-analyses in the general 
population have shown that there may be an association of both subclinical hypo- or 
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hyperthyroidism with increased CV events, particularly for extreme TSH values, but results 
remain conflicting (34) (36). These associations may be particularly important in patients with 
established AF, which are substantially different in comparison to the general population in 
terms of comorbidities and treatments (37). Furthermore, thyroid hormones may increase the 
sympathetic tone, alter ionic channels or decrease atrial refractory periods (37), while both 
subclinical hypothyroidism and hyperthyroidism may contribute to a hypercoagulable state 
(37, 38), effects which may be important in patients with established AF in respect of AF-
progression or development of CV events (37).  Previous small studies have suggested that 
hyperthyroidism may represent an independent risk factor for stroke in patients with AF and 
thus further contributing to the already increased risk (24), while this was not verified in 
larger populations (23, 25). In accordance with that, we did not find an increased risk for 
stroke or other CV events in patients with AF and subclinical hyperthyroidism. Nevertheless, 
our study may have been underpowered to detect these differences. According to our results 
the effect of subclinical hyperthyroidism on the composite endpoint had a range of 0.23 to 
1.32 (95% CI).  In the present study, we did not find any significant association between 
subclinical hypothyroidism and CV events, although a pattern of an association for higher 
TSH values could be discerned, which is consistent with other previous studies (2, 4, 5). For 
this subgroup, our study had fewer patients, which might explain the lack of statistical 
significance. Lastly, we examined if subclinical thyroid dysfunction was associated with AF-
progression, but did not find any significant association. 
Our results showed an association between higher fT4 and CV and HF hospitalization events 
in euthyroid participants with established AF. Results for HF hospitalizations, a particularly 
important outcome in the AF population (39), remained significant in sensitivity analyses 
excluding participants with substituted hypothyroidism or amiodarone treatment. The 
association with fT4 levels with CV events and mortality has been described in other studies 
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in the general population (8, 16, 40, 41). A prospective study in a cohort of 2843 community-
dwelling euthyroid individuals of > 65 years old has also examined the association of fT4 and 
HF events and have also shown an association between higher fT4 and HF events (HR 1.05, 
95%CI 1.02-1.09), while no association between TSH was detected (16). These results are 
consistent with the known physiological end-organ effect of free thyroid hormones on heart 
rate and pump function (37). As there is a loglinear relationship between TSH and fT4, it 
would be expected that thyroid function would be best represented by TSH levels. However 
we did not find this constellation. A possible explanation could be that in the older population 
pituitary reaction could be delayed and thus they could have a higher TSH norm than the 
young healthier population, as previously postulated (16). Our results may point the fact that 
fT4 measurement may be a more precise tool to predict HF events but additional research is 
needed to clarify if this association is causal and if so, through which mechanisms. In this 
direction, one recent Mendelian randomization study has assessed the association between 
fT4 and HF (34). Using data from the UK biobank, this study did not find a significant causal 
effect of thyroid function on HF in the general population (34). However, a limitation of this 
study was the low power in the analysis of HF as an outcome and more similar studies are 
needed. This is of particular clinical importance and should be further investigated in the AF 
population, since they already have an increased risk for HF (39). 
A quarter of patients within the highest quintile of fT4 levels among euthyroid individuals 
were on thyroid hormone supplementation. After excluding these subjects from the analyses, 
results remained significant for HF events but not for the composite CV events. This may be 
due to lower power of analyses in quintiles, or this could indirectly suggest that higher risk of 
composite CV events may be associated with an oversubstitution of previous (subclinical) 
hypothyroidism in patients with AF. More studies are needed to assess the effect of fT4 levels 
due to subclinical hypothyroidism treatment on CV events in such patients. This is crucial 
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considering common oversubstitution and overtreatment of subclinical hypothyroidism in 
patients with known cardiac co-morbidities (42). 
Among the strengths of our study, this is the first prospective cohort investigating subclinical 
thyroid dysfunction in the AF population. The prospective nature with careful design and 
collection of data increases the internal validity. In addition, we performed sensitivity 
analyses addressing many of the shortcomings of other studies in this field including thorough 
assessment of the impact of amiodarone treatment, potential competing risk of death, and a 
number of important subgroup analysis (33). Furthermore, the primary outcome was 
adjudicated through an independent committee.
Among the limitations of our study, TSH and fT4 were assessed only once at baseline and 
therefore we could not assess how many patients with subclinical dysfunction progressed to 
overt dysfunction or if the results were due to interactions with the assay. We reduced this 
limitation by performing sensitivity analyses excluding patients starting new thyroid treatment 
during follow-up. Furthermore, interindividual variability would be expected to attenuate 
rather than enhance underlying associations, as previously described (40). Second, fT3 was 
not measured. This is important for patients with subclinical hyperthyroidism since it may 
lead to a misclassification and thus underestimate the numbers of patients with overt 
hyperthyroidism. Nevertheless, this would be an issue in case in which an association between 
subclinical hyperthyroidism and adverse outcomes was found. A low fT3 level could be a 
reflection of a non-thyroidal illness, nevertheless, participants with any acute illness in the last 
4 weeks were excluded as per protocol and recruited only following recovering thus making 
non-thyroidal illness less possible. Third, in our study the female population represented a 
minority (27.2%), which is compatible with more male patients suffering from AF and 
therefore reflects an AF population (43). By nature of our cohort we cannot rule out a possible 
selection bias. Data collection on adults declining participation from one study site (Bern, 2nd 
Page 15 of 42 Accepted Manuscript published as EJE-20-1442.R4. Accepted for publication: 02-Jul-2021
Copyright © 2019 European Society of EndocrinologyDownloaded from Bioscientifica.com at 07/13/2021 08:07:06AM
via Universitatsbibliothek Bern and Universitat Bern
16
largest study site) indicated a possible selection bias due to non-participation and thus a 
possible healthy volunteer effect, unfortunately these data have not been collected in other 
study centers. Fourth, although our study is the first to investigate the association of 
subclinical thyroid dysfunction with AF-progression, this outcome was not adjudicated, and 
we did not have continuous ECG monitoring. Fifth, a considerable proportion of our 
participants was treated with amiodarone, a common treatment in patients with AF, which 
could have affected the thyroid function tests. Nevertheless, after excluding participants on 
amiodarone treatment in sensitivity analyses the association between fT4 and CV events was 
robust. In addition, data have suggested that amiodarone induced thyrotoxicosis with higher 
fT4 levels compared to lower fT4 may be associated with an increased CV risk (44). Sixth, 
our study had less power to detect meaningful differences between subclinical 
hyperthyroidism and CV events (80% power to detect a HR of 1.65). Finally, the data are 
observational and the possibility of residual confounding cannot be excluded.  
Conclusion
The analysis of this population-based prospective study showed that elderly patients with 
established AF and subclinical hypothyroidism did not have an increased risk of CV events. 
Subclinical hyperthyroidism was also not associated with CV events, even though our study 
had a lower power to detect these associations (80% power to detect a HR of 1.65).Higher 
levels of fT4 in euthyroid patients at baseline were associated with higher risk for HF 
hospitalizations. 
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Figure legends
Figure 1a. Age- and sex- adjusted CV events per 5 Units increase in fT4 in all euthyroid 
patients
Figure 1b. Age- and sex- adjusted CV events per 5 Units increase in fT4 excluding patients on 
amiodarone (n=308)
Figure 1c. Age- and sex- adjusted CV events per 5 Units increase in fT4 excluding patients on 
thyroid altering medications (n=175)
Abbreviations: CV: cardiovascular, HF: heart failure, HR: Hazard Ratio, MI: 
myocardial infarction, TIA: transient ischemic event 
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n (%) 2332 53 (2.3) 2004 (86.3) 196 (8.4) 83
Age, years 73.3± 8.4 73.5± 8.6 73.2± 8.5 73.3±8.2 72.5±8.8
Female 635 (27.2) 20 (37.7) 524 (26.2) 62 (31.6) 27 (32.5)
BMI, kg/m2 27.7± 4.8 27.9± 4.5 27.6±4.8 27.8± 5.1 28.3±4.6
Smoking a
Never 1020 (43.8) 30 (56.6) 869 (43.4) 91 (46.4) 38 (45.8)
Past 1140 (48.9) 19 (35.9) 989 (49.4) 88 (44.9) 39 (47.0)
Current 170 (7.3) 4 (7.6) 144 (7.2) 17 (8.7) 6 (7.3)
TSH mIU/L 2.0 (1.3-3.0) 0.3 (0.1-0.4) 1.9 (1.3-2.7) 5.8 (4.9-7.5) -
FT4 pmol/L 16.0 (14.4-18.3) 17.5 (15.9-19.3) 16.0 (14.4-18.2) 15.4 (14.1-17.3) -
Thyreostatic use 19 (0.8) 5 (9.4) 6 (0.3) 4 (2.0) 2 (2.4)
Thyroid hormones use 229 (9.8) 16 (30.2) 151 (7.5) 39 (19.9) 10 (12.0)
Hypertension 1623 (69.9) 39 (73.6) 1387 (69.2) 136 (69.4) 59 (71.1)
Diabetes 405 (17.4) 4 (7.5) 347 (17.3) 36 (18.4) 6 (7.2)
Hypothyroidism 230 (11.2) 16 (30.2) 157 (7.8) 56 (28.6) 10 (12.0)
Hyperthyroidism 89 (3.8) 8 (15.9) 59 (2.9) 13 (6.6) 6 (7.2)
Known cardiovascular diseaseb 789 (33.6) 10 (18.9) 674 (33.6) 70 (35.7) 32 (38.6)
Previous electro conversion 830 (35.6) 20 (37.7) 689 (34.4) 82 (41.8) 31 (37.3)
History of heart failurec 608 (26.1) 7 (13.2) 503 (25.1) 65 (33.2) 18 (21.7)
Baseline statin 1144 (49.1) 28 (52.8) 982 (49.0) 93 (47.5) 45 (54.2)
Baseline amiodarone 407 (17.5) 4 (7.6) 308 (15.4) 63 (32.1) 17 (20.5)
*All participants with available blood samples; n=79 participants with clinical hypothyroidism or hyperthyroidism not depicted in the table; Abbreviations: BMI: 
body mass index
 an=2 missing, bCardiovascular disease defined as previous myocardial infarction, bypass, peripheral arterial disease, cn=1 missing
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Table 2. Cardiovascular events and all-cause mortality by subclinical thyroid status at baseline in all participants
Thyroid Status Euthyroidism 
with TSH
Subclinical Hyperthyroidism with TSH
0.45-4.49 mIU/L
(n=2004)
<0.45mIU/L (n=53) 4.5-19.9 mIU/L (n=196) 4.5-7 mIU/L (n=129) 7-19.9 mIU/L (n=67)
 Events Events HR (95% CI)* Events HR (95% CI)* Events HR (95% CI)* Events HR (95% CI)*
Composite endpoint 338  5 0.55 (0.23-1.32) 33 0.99 (0.69-1.41)  18  0.84 (0.52-1.35) 15 1.27 (0.76-2.13) 
Stroke/TIA 79 1 0.46 (0.06-3.33 7 0.88 (0.41-1.92) 4 0.81 (0.30-2.21) 3 1.01 (0.32-3.21)
MI 46 2 1.89 (0.46-7.80) 6 1.51 (0.64-3.56) 5 1.95 (0.77- 4.95) 1 0.71 (0.10-5.15)
HF-events 191 3 0.59 (0.19-1.83) 17 0.90 (0.55-1.48) 7 0.57 (0.27-1.20) 10 1.55 (0.82-2.93)
CV death 112 1 0.36 (0.05-2.55) 11 1.06 (0.57-1.96) 7  1.07 (0.50-2.30) 4 1.03 (0.38-2.80) 
Total Mortality 164 2 0.48 (0.11-1.95) 17 1.09 (0.66-1.79) 9 0.92 (0.47-1.81) 8 1.37 (0.67-2.79)
BMI: body mass index, CV: cardiovascular, HF: heart failure, HR: Hazard Ratio, MI: myocardial infarction, TIA: transient ischemic event.
 Age/sex- adjusted
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Table 3. Cardiovascular events and all-cause mortality by fT4 in quintiles in euthyroid participants at baseline (n=2004).
FT4 Quintiles IQR
12.0-13.5 (n=383) 14.4-15.0 (n=411) 15.7-16.3 (n=413) 17.2-18.3 (n=416) 19.7-22.8 (n=381)
Events HR (95% CI)* Events HR (95% CI)* Events HR (95% CI)* Events HR (95% CI)* Events HR (95% CI)*
Composite endpoint 59 1.08 (0.76-1.54) 62 1.00 (0.70-1.40) 65 1.00 80 1.38 (0.99-1.91) 72 1.46 (1.04-2.05)a
Stroke/TIA 20 1.49 (0.77-2.88) 10 0.64 (0.29-1.43) 16 1.00 21 1.44 (0.76-2.78) 12 0.90 (0.42-1.92)
MI 5 0.49 (0.17-1.39) 8 0.70 (0.29-1.72) 11 1.00 9 0.72 (0.29-1.76) 8 0.85 (0.34-2.10)
HF-events 27 0.92 (0.56-1.53) 39 1.19 (0.76-1.90) 34 1.00 45 1.47 (0.94-2.29) 46 1.70 (1.08-2.66)a
CV death 18 1.02 (0.54-1.92) 23 1.17 (0.65- 2.11) 21 1.00 28 1.51 (0.86-2.82) 22 1.54 (0.84-2.81)
Total mortality 28 1.10 (0.67-1.84) 35 1.23 (0.75-2.00) 30 1.00 40 1.49 (0.93-2.40) 31 1.47 (0.88-2.43)
BMI: body mass index, CV: cardiovascular, HF: heart failure, HR: Hazard Ratio, MI: myocardial infarction, TIA: transient ischemic event ap<0.05 
*age/sex adjusted
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Figure 1a. Age- and sex- adjusted CV events per 5 Units increase in fT4 in all euthyroid patients 
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Figure 1b. Age- and sex- adjusted CV events per 5 Units increase in fT4 excluding patients on amiodarone 
(n=308) 
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Figure 1c. Age- and sex- adjusted CV events per 5 Units increase in fT4 excluding patients on thyroid 
altering medications (n=175) 
408x257mm (600 x 600 DPI) 
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Appendix Table 1a. Cardiovascular events and all-cause mortality by subclinical thyroid status at baseline in all participants (multivariable models) (N=2332)
Subclinical Hyperthyroidism 
with TSH <0.45mIU/L
Subclinical Hypothyroidism with 
TSH 4.5-19.9mIU/L
Subclinical Hypothyroidism with 
TSH 4.5-7mIU/L


























Composite endpoint 0.57 (0.23-1.37) 0.58 (0.24-1.42) 0.99 (0.69-1.42) 0.95 (0.66-1.37) 0.85 (0.53-1.36) 0.84 (0.52-1.35) 1.24 (0.74-2.08) 1.14 (0.67-1.95)
Stroke/TIA 0.47 (0.07- 3.39) 0.47 (0.06-3.41) 0.88 (0.40- 1.90) 0.95 (0.43-2.10) 0.81 (0.30-2.22) 0.87 (0.32-2.40) 0. 98 (0.31-3.11) 1.08 (0.33-3.55)
MI 1.93 (0.47-8.04) 2.23 (0.52-9.6) 1.49 (0.63-3.5) 1.12 (0.44-2.87) 1.98 (0.78-5.01) 1.44 (0.54-3.87) 0.67 (0.10-4.90) 0.50 (0.06-3.93)
HF-events 0.62 (0.19-1.95) 0.75 (0.24-2.39) 0.90 (0.55- 1.47) 0.88 (0.53-1.46) 0.57 (0.27-1.21) 0.58 (0.27-1.24) 1.50 (0.79-2.84) 1.40 (0.72-2.72)
CV death 0.42 (0.06-3.03) 0.36 (0.05-2.58) 1.06 (0.57-1.97) 0.91 (0.48-1.73) 1.08 (0.50-2.32) 0.95 (0.43-2.06) 1.03 (0.38-2.80) 0.88 (0.31-2.45)
Total Mortality 0.50 (0.12-2.03) 0.49 (0.12-2.00) 1.08 (0.66-1.78) 1.02 (0.61-1.71) 0.94 (0.48-1.84) 0.89 (0.45-1.76) 1.30 (0.64-2.66) 1.22 (0.58-2.55)
Abbreviations: BMI: body mass index, CV: cardiovascular, HF: heart failure, HR: Hazard Ratio, MI: myocardial infarction, TIA: transient ischemic event. The 
euthyroidism group was used as the reference group; For number of events see Table 2
 aadjusted for age, sex, BMI, smoking status badjusted for: age, sex, BMI, smoking status, previous diabetes, previous cardiovascular disease, previous heart 
failure, previous electro conversion, baseline use of amiodarone, baseline use of thyroid hormones or known previous hypothyroidism 
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Appendix Table 1b. Cardiovascular events and all-cause mortality by subclinical thyroid status at baseline in participants according to cardiovascular disease 
at baseline (N=2332)
Thyroid Status
Subclinical Hyperthyroidism with 
TSH <0.45mIU/L














Composite endpoint 2/10 0.84 (0.21-3.41) 0.633 18/70 0.89 (0.52-1.51) 0.165
HF-events 1/10 0.68 (0-09-4.91) 0.746 7/70 0.67 (0.31-1.45) 0.444
Patients without CV-
disease
Composite endpoint 3/43 0.48 (0.15-1.51) 0.214 18/126 1.05 (0.65-1.71) 0.869
HF-events 2/43 0.61 (0.15-2.50) 0.499 10/126 1.08 (0.56-2.08) 0.746
Abbreviations: CV: cardiovascular, HF: heart failure, HR: Hazard Ratio
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 HR (95% CI)Age/sex adjusted model 
HR (95% CI)
multivariable model a
Composite endpoint 1.05 (0.99-1.11) 1.05 (0.99-1.10)
Stroke/TIA 1.03 (0.92-1.15) 1.03 (0.92-1.14)
MI 1.04 (0.89-1.21) 1.03 (0.89-1.21)
HF-events 1.05 (0.98-1.13) 1.05 (0.98-1.12)
CV death 1.06 (0.97-1.16) 1.06 (0.97-1.16)
Total Mortality 1.06 (0.98-1.14) 1.06 (0.98-1.14)
Abbreviations: BMI: body mass index, CV: cardiovascular, HF: heart failure, HR: Hazard Ratio, MI: myocardial infarction, TIA: transient ischemic event
 aadjusted for age, sex, BMI and smoking status 
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Subclinical Hyperthyroidism with TSH <0.45mIU/L
N=33
Subclinical Hypothyroidism with TSH 4.5-
19.9mIU/L
N=153
 Events Events HR (95% CI)age/sex adjusted
HR (95% CI)





Composite endpoint 308 4 0.74 (0.27-1.97) 0.75 (0.28-2.01) 21 0.79 (0.51-1.23) 0.79 (0.51-1.23)
Stroke/TIA 73 1 0.74 (0.10-5.30) 0.75 (0.10-5.44) 6 0.95 (0.41-2-18) 0.95 (0.41-2.17)
MI 36 2 3.50 (0.84-14.6) 3.64 (0.87-15.25) 5 1.63 (0.64-4.17) 1.63 (0.64-4.15)
HF-events 178 2 0.66 (0.16-2.65) 0.66 (0.16-2.67) 12 0.78 (0.43-1.40) 0.77 (0.43-1.39)
CV death 101 1 0.61 (0.08-3.74) 0.61 (0.08-4.36) 5 0.60 (0.24-1.48) 0.61 (0.25-1.49)
Total Mortality 148 2 0.80 (0.20-3.23) 0.80 (0.19-3.22) 11 0.89 (0.48-1.64) 0.89 (0.48-1.64)
Abbreviations: BMI: body mass index, CV: cardiovascular, HF: heart failure, HR: Hazard Ratio, MI: myocardial infarction, TIA: transient ischemic event
 a participants with thyroid altering medications at baseline N=247; One participant reported to have both thyreostatic medications and thyroid hormones. 
bAdjusted for age, sex, BMI, smoking status; The euthyroidism group was used as the reference group
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Appendix Table 4. Cardiovascular events and all-cause mortality by subclinical thyroid status (competing risks models) in all participants (N=2332)
 Subclinical Hyperthyroidism with TSH <0.45mIU/L(N=53)
Subclinical Hypothyroidism with TSH 4.5-19.9mIU/L
(N=196)
 SHR (95% CI)age/sex adjusted
SHR (95% CI)
age/sex adjusted
Composite endpoint 0.57 (0.24-1.36) 0.99 (0.69-1.43)
Stroke/TIA 0.49 (0.07-3.56)  0.86 (0.39-1.87)
MI 1.99 (0.48-8.23) 1.48 (0.63-3.48)
HF-events 0.64 (0.21-1.92) 0.87 (0.52-1.43)
CV death  0.36 (0.05-2.69) 1.07 (0.57-2.01) 
Abbreviations: CV: cardiovascular, HF: heart failure, HR: Hazard Ratio, MI: myocardial infarction, SHR: Subhazard ratio, TIA: transient ischemic event 
 a adjusted for age, sex, BMI, smoking status
Page 33 of 42 Accepted Manuscript published as EJE-20-1442.R4. Accepted for publication: 02-Jul-2021
Copyright © 2019 European Society of Endocrinology Downloaded from Bioscientifica.com at 07/13/2021 08:07:06AM
via Universitatsbibliothek Bern and Universitat Bern










All Euthyroid Participants (N=2004)
Composite endpoint 1.16 (1.10-1.28)b 1.16 (1.10-1.28)b
Stroke/TIA  0.95 (0.66-1.34) 0.95 (0.66-1.34)
MI  0.95 (0.73-1.40) 1.00 (0.70-1.40)
HF-events 1.22 (1.10-1.34)b 1.22 (1.16-1.34)b
CV death 1.10 (1.05-1.22)b 1.10 (1.05-1.22)b
Total Mortality 1.10 (1.00-1.16)b 1.10 (1.00-1.22)b
Excluding euthyroid participants with amiodarone
at baseline (N=1696)
Composite endpoint 1.16 (1.10-1.28)b  1.19 (1.10-1.27)b
Stroke/TIA 1.05 (0.86-1.28)  1.05 (0.86-1.27)
MI 1.00 (0.77-1.40)  1.05 (0.77-1.40)
HF-events 1.22 (1.10-1.28)b  1.22 (1.16-1.34)b
CV death 1.10 (0.95-1.22)  1.10 (1.00-1.21)b
Total Mortality 1.10 (1.00-1.16)b  1.10 (1.05-1.16)b
Excluding euthyroid participants with thyroid
altering medications at baseline 
and follow up (N=1829)
Composite endpoint 1.16 (1.10-1.28)b  1.16 (1.05-1.27)b
Stroke/TIA 0.82 (0.53-1.28)  0.77 (0.52-1.22)
MI 0.95 (0.62-1.54)  0.95 (0.62-1.53)
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HF-events 1.22 (1.10-1.28)b  1.22 (1.10-1.34)b
CV death 1.10 (0.95-1.22)  1.10 (0.95-1.22)
Total Mortality 1.10 (0.95-1.16)  1.05 (0.95-1.22)
Abbreviations: BMI: body mass index, CV: cardiovascular, HF: heart failure, HR: Hazard Ratio, MI: myocardial infarction, TIA: transient ischemic event
 a adjusted for age, sex, BMI, smoking status; bp<0.05
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Appendix Table 6. Baseline characteristics of included participants according to fT4 quintiles (N=2332)
Variable Lowest fT4 Quantile (n=468)
Second fT4 Quantile 
(n=465)




Highest fT4 Quantile 
(n=466)
Age, y (mean, SD) 73.4 (8.50) 73.3 (8.2) 73.5 (8.3) 73.2 (9.0) 73.0 (7.9)
Female (n, %) 107 (22.8) 108 (23.2) 115 (24.6) 127 (27.3) 178 (38.8)




















Sport (yes) (n, %)a 211, 45.1 222, 47.7 228, 48.9 203, 43.6 207, 44.5
Units of alcohol consumption 
(median, IQR)a 0.6 (0.1 -1.6) 0.6 (0.1-1.4) 0.6 (0.1- 1.3) 0.5 (0.1- 1.2) 0.3 (0.1-1.0)
TSH mIU/L (median, IQR) 2.5 (1.6-3.9) 2.1 (1.4-3.0) 1.9 (1.4-2.8) 1.9 (1.2-2.7) 1.7 (1.0-2.6)




















Use of thyroid medication:
Thyreostatic (n, %) 7 (1.5) 6 (1.3) 1 (0.2) 2 (0.4) 3 (0.4)
Use of thyroid medication:
Thyroid hormones (n, %) 11 (2.4) 18 (3.9) 26 (5.6) 53 (11.3) 121 (25.7)
Hypertension (n, %) 312 (66.7) 313 (67.3) 328 (70.2) 336 (72.1) 334 (71.7)
History of diabetes (n, %) 79 (16.9) 77 (16.6) 76 (16.3) 88 (18.8) 85 (18.2)
Previous hypothyroidism (n, %) 35 (7.5) 24 (5.2) 29 (6.2) 51 (10.9) 121 (26.0)
Previous hyperthyroidism (n, %) 20 (4.3) 25 (5.4) 16 (3.4) 14 (3.0) 14 (3.0)
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History of CVDb (n, %) 139 (29.7) 161 (34.6) 139 (29.8) 168 (36.1) 176 (37.8)
Previous electroconversion (n, %) 141 (30.1) 146 (31.4) 139 (29.8) 181 (38.8) 223 (47.9)
History of heart failure (n, %)c 105 (22.5) 103 (22.2) 117 (25.1) 134 (28.6) 149 (32.0)
Baseline statin (n, %) 208 (44.4) 238 (51.2) 226 (48.4) 235 (50.4) 237 (50.9)
Baseline amiodarone (n, %) 28 (6.0) 29 (6.2) 48 (10.3) 92 (19.7) 210 (45.1)
Baseline ACEI (n, %) 130 (27.8) 149 (32.0) 143 (30.6) 163 (34.9) 151 (32.4)
Baseline ARBs (n, %) 125 (26.7) 131 (28.2) 148 (31.7) 149 (32.0) 168 (36.1)
Abbreviations: ACEIs: Angiotensin converting enzymes, AF: atrial fibrillation, ARBs: Angiotensin II receptor blockers, BMI: body mass index CVD: cardiovascular 
disease; an=2 missing;  bCVD defined as previous myocardial infarction, bypass, peripheral arterial disease; cn=1 missing 
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Appendix Table 7. Cardiovascular events and all-cause mortality by fT4 quintiles at baseline in euthyroid participants excluding participants with 















































































































































*Participants on amiodarone N=308; Abbreviations: BMI: body mass index, CV: cardiovascular, HF: heart failure, HR: Hazard Ratio, MI: myocardial infarction, 
TIA: transient ischemic event
 aadjusted for: age, sex, BMI, smoking status bp<0.05
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Abbreviations: BMI: body mass index, CV: cardiovascular, HF: heart failure, HR: Hazard Ratio, MI: myocardial infarction, TIA: transient ischemic event; For 
number of events see Table 3;
 aadjusted for: age, sex, BMI, smoking status  badjusted for: age, sex, BMI, smoking status, previous cardiovascular disease, previous heart failure, previous 
electroconversion, baseline use of amiodarone, baseline use of thyroid hormones, previous hypothyroidism  cp<0.05
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Appendix Table 9. Cardiovascular events by fT4 quintiles at baseline in euthyroid participants excluding participants with thyroid altering medications at 
baseline and during follow-up (N=1829)*









Events HR (95% CI)
age/sex-adjusted
Events HR (95% CI)
age/sex-adjusted
Events HR (95% CI)
age/sex-adjusted
Events HR (95% CI)
age/sex-adjusted
Events HR (95% CI)
age/sex-adjusted
Composite endpoint 58 1.11 (0.78-1.59) 62 1.06 (0.74-1.51) 61 1.00 71 1.39 (0.98-1.96) 52 1.36 (0.94-1.97)
HF-events 27 1.03 (0.61-1.73) 39 1.36 (0.84-2.19) 30 1.00 43 1.72 (1.08-2.75)a 35 1.83 (1.12-2.98) a
*Participants with thyroid altering medications at baseline(N=157) and during follow-up (N=18); Abbreviations: HF: Heart Failure, HR: Hazard Ratio; ap<0.05
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Appendix Table 10. Cardiovascular events and all-cause mortality by fT4 quintiles (competing risks models) in euthyroid participants (N=2004)
FT4 Quintiles IQR 12.0-13.5 14.4-15.0 15.7-16.3 17.2-18.3 19.7-22.8









Composite endpoint 1.07 (0.75-1.52) 0.98 (0.69-1.39) 1.00 1.37 (0.99-1.91) 1.46 (1.03-2.06)a
Stroke/TIA 1.49 (0.77-2.90) 0.64 (0.29-1.42) 1.00 1.42 (0.74-2.74) 0.90 (0.43-1.92)
MI 0.54 (1.19-1.55) 0.77 (0.31-1.92) 1.00 0.88 (0.36-2.14) 0.90 (0.36-2.26)
HF-events 0.92 (0.55-1.53) 1.19 (0.75-1.90) 1.00 1.45 (0.93-2.27) 1.68 (1.07-2.64)a
CV death 1.01 (0.54-1.88) 1.15 (0.63-2.05) 1.00 1.50 (0.85-2.62) 1.54 (0.83-2.85)
Abbreviations: CV:cardiovascular, HF: heart failure, MI: myocardial infarction, SHR: Subhazard Ratio, TIA: transient ischemic event
 ap<0.05
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Appendix Table 11. Association between subclinical thyroid status and AF-progression in all participants (N=2332)
Euthyroidism with TSH 0.45-
4.49mIU/L
Subclinical Hyperthyroidism with TSH 
<0.45mIU/L
Subclinical Hypothyroidism with TSH 4.5-
19.9mIU/L
Events/N Events/N HR (95% CI)age/sex adjusted Events/N
HR (95% CI)
age/sex adjusted
Clinical AF Progression 247/2004 8/53 1.08 (0.53-2.18) 24/196 1.05 (0.69-1.60)
Pharmacological AF 
Progressiona 205/1696 8/49 1.24 (0.61-2.51) 18/133 1.22 (0.75-1.99)
Abbreviations: HR: Hazard Ratio aexcluding participants with amiodarone at baseline (n=407)
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